Chondroitin and Hyaluronic Acid: what the published research says
PubMed indexes 8 records that name Chondroitin and Hyaluronic Acid together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Chondroitin and Hyaluronic Acid. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
A study appearing here is not proof that an interaction exists. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
NutriStack’s own interaction assessment for this pair is not published here. It has not completed qualified-human clinical review, so it is withheld from search. See the publication gate.
Nothing here is medical advice. Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen.
The research
8 studies naming Chondroitin and Hyaluronic Acid.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
“The use of HA/ChS resulted in a significant improvement in pain as well as voiding and irritative symptoms in all the investigated conditions. In addition, the treatment reduced the risk of rUTI when compared to standard care. Although limited data were available, when randomised controlled trials were investigated, the combined use of HA/ChS resulted in better outcomes and a lower infection rate compared to either placebo or standard of care (odds ratio 0.42 [95% CI 0.25…”
Names both Chondroitin and Hyaluronic Acid in its title.
International urogynecology journal · 2018 · PMID 29181550
Meta-AnalysisSystematic ReviewHuman subjects
“HA ± CS appears to reduce the rate of UTI and increase the time to recurrence in women with RUTI. As randomized controlled studies are available only for HA plus CS, the quality of evidence is higher for the combination than for HA alone.”
Names both Chondroitin and Hyaluronic Acid in its title.
The journal of sexual medicine · 2024 · PMID 38721680
Randomized Controlled Trial
“The oral formulation of HA, chondroitin sulfate, N-acetylglucosamine, and vitamin C could be an effective therapy against urinary and sexual distress in participants with rUTI (NCT06268483; ClinicalTrials.gov).”
Names both Chondroitin and Hyaluronic Acid in its title.
Therapeutic advances in gastroenterology · 2025 · PMID 40520453
Review
“These treatments aim to prevent acid from damaging the esophagus or to create a protective barrier around it. Recently introduced medical devices containing hyaluronic acid (HA) and chondroitin sulfate (CS) that stick to the esophagus offer good protection of the esophageal mucosa, ultimately aiming to provide better results and a better quality of life for patients.”
Names both Chondroitin and Hyaluronic Acid in its title.
International journal of molecular sciences · 2022 · PMID 35163608
Human subjects
Names both Chondroitin and Hyaluronic Acid in its title.
Limitations
What this evidence cannot tell you.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.
Nearby evidence
Other pairs with published research.
Pages covering Chondroitin or Hyaluronic Acid alongside a different substance.
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Chondroitin, Hyaluronic Acid, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
